以岭药业
(002603)
| 流通市值：246.59亿 | | | 总市值：299.22亿 |
| 流通股本：13.77亿 | | | 总股本：16.71亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,867,603,073.61 | 4,040,142,217.94 | 2,358,232,707.77 | 6,512,734,471.77 |
| 营业收入 | 5,867,603,073.61 | 4,040,142,217.94 | 2,358,232,707.77 | 6,512,734,471.77 |
| 二、营业总成本 | 4,704,006,732.64 | 3,245,278,851.39 | 1,946,902,188.1 | 7,147,123,381.22 |
| 营业成本 | 2,315,869,844.22 | 1,637,009,460.27 | 1,088,979,435.66 | 3,244,208,648.07 |
| 税金及附加 | 94,880,945.65 | 64,814,738.42 | 30,250,648.89 | 119,211,877.27 |
| 销售费用 | 1,352,967,439.64 | 913,223,536.33 | 547,039,894.43 | 2,334,704,305.07 |
| 管理费用 | 398,090,659.13 | 273,783,670.3 | 117,453,827.72 | 600,011,013.3 |
| 研发费用 | 544,012,861.24 | 358,284,639.01 | 164,030,341.5 | 826,572,646.79 |
| 财务费用 | -1,815,017.24 | -1,837,192.94 | -851,960.1 | 22,414,890.72 |
| 其中:利息费用 | 760,671.95 | 401,838.23 | 139,827.92 | 29,006,743.88 |
| 其中:利息收入 | 5,256,531.37 | 3,448,412.32 | 1,467,295.44 | 8,001,089.51 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -113,080.5 | -80,573.67 | -495,638.12 | 39,808,208.41 |
| 资产处置收益 | -358,873.93 | 14,191.17 | -87.07 | -487,181.84 |
| 资产减值损失(新) | -37,735,638.42 | -23,365,676.47 | -20,228,830.71 | -248,337,301.39 |
| 信用减值损失(新) | 5,032,693.38 | 1,210,238.46 | 2,150,899.78 | -10,297,019.75 |
| 其他收益 | 56,884,631.1 | 48,894,821.57 | 5,815,450.27 | 164,806,751.97 |
| 四、营业利润 | 1,187,306,072.6 | 821,536,367.61 | 398,572,313.82 | -688,895,452.05 |
| 加:营业外收入 | 10,772,771.7 | 7,972,964.98 | 6,268,964.61 | 10,472,588.05 |
| 减:营业外支出 | 28,443,444.08 | 25,855,573.05 | 10,720,228.07 | 121,769,143.83 |
| 五、利润总额 | 1,169,635,400.22 | 803,653,759.54 | 394,121,050.36 | -800,192,007.83 |
| 减:所得税费用 | 172,961,064.32 | 138,355,469.1 | 69,965,135.6 | -66,008,475.57 |
| 六、净利润 | 996,674,335.9 | 665,298,290.44 | 324,155,914.76 | -734,183,532.26 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 996,674,335.9 | 665,298,290.44 | 324,155,914.76 | -734,183,532.26 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,000,404,671.91 | 668,535,024.73 | 325,953,296.25 | -724,515,582.24 |
| 少数股东损益 | -3,730,336.01 | -3,236,734.29 | -1,797,381.49 | -9,667,950.02 |
| 扣除非经常损益后的净利润 | 966,453,850.25 | 641,355,642.22 | 325,059,321.37 | -792,499,673.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.6 | 0.4 | 0.2 | -0.43 |
| (二)稀释每股收益 | 0.6 | 0.4 | 0.2 | -0.43 |
| 八、其他综合收益 | 96,367.62 | -115,833.71 | -54,894.21 | -507,389.2 |
| 归属于母公司股东的其他综合收益 | 96,367.62 | -115,833.71 | -54,894.21 | -507,389.2 |
| 九、综合收益总额 | 996,770,703.52 | 665,182,456.73 | 324,101,020.55 | -734,690,921.46 |
| 归属于母公司股东的综合收益总额 | 1,000,501,039.53 | 668,419,191.02 | 325,898,402.04 | -725,022,971.44 |
| 归属于少数股东的综合收益总额 | -3,730,336.01 | -3,236,734.29 | -1,797,381.49 | -9,667,950.02 |
| 公告日期 | 2025-10-28 | 2025-08-28 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |